Research · Sep 3, 2026
[LNTH] Lantheus Holdings Thesis 2026: PYLARIFY Scales While a Radioligand-Therapy Pipeline Opens a Bigger Market
Lantheus Holdings, Inc. (NASDAQ: LNTH) is a North Billerica, Massachusetts-headquartered radiopharmaceutical company — manufacturing, marketing and distributing diagnostic imaging agents and radioligand therapies for use principally in oncology, cardiology and neurology. The company traces back to DuPont Pharmaceutical's medical-imaging business (acquired by BMS, renamed BMS Medical Imaging), then carved out in 2008 as Lantheus Medical Imaging by Avista Capital; went public on NASDAQ in 2015 as Lantheus Holdings and transformed itself from a legacy medical-imaging company into a specialty radiopharma leader through the 2021 FDA approval and commercial launch of PYLARIFY, the 2022 acquisition of Cerveau Technologies (MK-6240 Alzheimer's-PET imaging program), and most consequentially the 2024 ~$2B+ acquisition of POINT Biopharma/PNT Therapeutics (bringing PNT2002, a Phase 3 PSMA-targeted radioligand therapy). The commercial portfolio: PYLARIFY (piflufolastat F-18 PSMA-targeted PET imaging for prostate cancer — ~$1.3-1.6B+ annual, ~70-80% of company), DEFINITY (perflutren microsphere ultrasound contrast for cardiac echo — ~$250-320M, ~15-20%), TechneLite (Tc-99m radiopharmaceutical generator — DuPont legacy, ~$100-150M, declining). The pipeline includes PNT2002 (Phase 3), MK-6240 (Phase 3 Alzheimer's-PET), NM-01 (cardiac late-stage), other earlier-stage. Geography is principally US (PYLARIFY US-only commercial; ex-US partnered). Capital structure carries modest post-PNT leverage with strong FCF. Mary Anne Heino led the transformation as CEO 2015-2024; Paul Blanchfield (ex-COO) became CEO mid-2024; Brian Markison is Executive Chairman. LNTH enters FY2026 with FY2025 revenue selected various aggregate ~$1.5-1.8B, aggregate adjusted EPS ~$6.50-7.75, adjusted EBITDA ~$580-680M (~36-40% margin). The first thesis pillar is PYLARIFY — the blockbuster PSMA-PET diagnostic, the largest single growth driver: PYLARIFY is an F-18-labeled PSMA-targeted PET imaging agent — PSMA (prostate-specific membrane antigen) overexpressed on prostate cancer cells, F-18 PET-compatible isotope attached to a PSMA-binding ligand allowing precise visualization on PET — FDA-approved May 2021 for diagnostic identification of prostate-cancer recurrence and metastasis in adult men with elevated PSA, replacing older bone-scan/CT/MRI imaging modalities with dramatically better sensitivity and specificity; the PSMA-PET market ~$1.5-2.0B+ US annual and growing, with PYLARIFY ~60-70%+ market share; competitors: Blue Earth Diagnostics/Bayer's Posluma (flotufolastat F-18, FDA-approved 2023, ~10-20% share with continued growth), Telix Pharmaceuticals's Illuccix (Ga-68 PSMA-11, FDA-approved 2021, ~10-15% share); the reimbursement dynamic — PYLARIFY benefits from Medicare's transitional pass-through ('TPT') status providing separate payment for radiopharmaceuticals at outpatient hospital settings (higher-margin channel) — TPT status time-limited and subject to renewal/expiration; FY2025 dynamics are PYLARIFY net revenue growing mid-to-high-single-digit % (strong volumes, partially offset by competitive pricing pressure), reimbursement holding, clinical-utility expanding into newer use cases (post-prostatectomy BCR, treatment-monitoring); FY2026 catalyst is continued net-revenue growth, Medicare TPT renewal, payer mix, clinical utility, additional indications; risks/competitors are Posluma/Illuccix share gains, Medicare TPT expiration, manufacturing/supply complexity (F-18 short-half-life), and US PSMA-PET market maturation — comps include GE HealthCare (GEHC), Bayer (BAYRY), Telix (TLX), Curium (private), Eckert & Ziegler (private), and on prostate-cancer-treatment Novartis (NVS), Astellas (ALPMY), Pfizer (PFE). The second pillar bundles the RLT pipeline (the major value-creation beyond PYLARIFY) with DEFINITY/TechneLite: PNT2002 (2024 ~$2B+ POINT Biopharma acquisition) — 177Lu-labeled PSMA-targeted RLT for mCRPC in Phase 3 SPLASH — a direct competitor to Novartis's Pluvicto (177Lu-PSMA-617, FDA-approved 2022, $1B+ run-rate) — strategic logic is the 'diagnose with PYLARIFY → treat with PNT2002' radiopharma flywheel covering the prostate-cancer treatment pathway; FY2025 dynamics are PNT2002 Phase 3 data maturing, FDA engagement, PNT integration; FY2026 catalyst is Phase 3 readout / NDA filing / potential approval — the major asymmetric upside; DEFINITY (#1 echo contrast US, ~$250-320M annual, on patent ~2025-2030 by formulation) — steady cash engine with GE HealthCare's Optison as main competitor and selective generic-substitution risk late-decade; TechneLite (Tc-99m generator DuPont legacy ~$100-150M, declining as F-18/Ga-68 PET takes share); broader pipeline — MK-6240 (Phase 3 Alzheimer's-PET tau imaging with Cerveau), NM-01 (cardiac late-stage), neurology/oncology/RLT earlier-stage; FY2025 dynamics are pipeline progressing, PNT integration, DEFINITY modest growth; FY2026 catalyst is PNT2002 readout (the big binary), pipeline data, additional tuck-in M&A; risks/competitors are PNT2002 trial failure, Pluvicto's commercial entrenchment (Novartis salesforce/marketing/supply), other RLT competitors (Bayer/Curium PSMA-RLT, Telix TLX591), DEFINITY generic timing, lutetium-177 supply complexity — comps include Novartis (NVS), Telix (TLX), Curium (private), Bayer (BAYRY), Eckert & Ziegler (private), and specialty pharma Halozyme (HALO), Catalyst (CPRX), Insmed (INSM). The capital story: a token-or-no dividend (historically no regular dividend, focus on growth investment + balance sheet), selective opportunistic buybacks (~68-72M shares roughly flat-to-slightly-down), net debt ~$0.7-1.4B (senior notes + term loan/revolver + PNT-assumed debt, manageable post-deal), ~1.0-2.0x net debt/EBITDA (modest), near-IG / IG-equivalent (BB+/Ba1 or BBB-/Baa3-area on positive trajectory), strong FCF supporting deleveraging, capital priorities fund pipeline (PNT2002, MK-6240, RLT programs) → bolt-on radiopharma M&A → deleveraging → selective buybacks → potential dividend later — with post-PNT deleveraging pace, PYLARIFY reimbursement, PNT2002 outcome, M&A capacity, and rate environment as the principal considerations. At ~$50-90 per share on ~68-72M shares (~$3.5-6.5B equity, ~$4.0-7.5B EV) LNTH trades at roughly ~9-14x P/E, ~7-12x EV/EBITDA and ~10-15x EV/FCF — discounted versus pre-2024 sentiment (>20x P/E on PYLARIFY growth) reflecting competitive concerns (Posluma + Illuccix), Medicare TPT uncertainty, PNT2002 binary, and PNT integration; the bull case is multiple re-expansion as PYLARIFY share holds, PNT2002 reads out, and the diagnose+treat flywheel commands a strategic premium — versus GE HealthCare (GEHC, Blue Earth parent), Telix (TLX), Bayer (BAYRY), Novartis (NVS, Pluvicto), Bracco (private), Curium (private), Eckert & Ziegler (private), specialty pharma Halozyme (HALO), Catalyst Pharmaceuticals (CPRX), Insmed (INSM), Ironwood (IRWD), and medical-imaging diversified GE HealthCare (GEHC), Philips (PHG), Siemens Healthineers (SHL.DE). FY2026 base case: ~$1.6-1.85B revenue + ~$7.00-8.25 adj. EPS + ~$620-720M adjusted EBITDA + PYLARIFY revenue growth holding + DEFINITY steady + PNT2002 progressing + deleveraging + pipeline flowing; bull case: ~$1.75-2.1B+ revenue + ~$8.00-10.00+ adj. EPS on PYLARIFY share defense, Medicare TPT renewed, PNT2002 Phase 3 positive and on track for 2026-2027 approval/launch (transformative), diagnose+treat franchise strategic premium, accretive M&A, possible dividend, and a re-rating; bear case: ~$1.4-1.6B revenue + ~$5.50-6.50 adj. EPS on Posluma/Illuccix taking PYLARIFY share, Medicare TPT expiration, PNT2002 failure/delay, DEFINITY generic earlier, PNT integration challenges, and compression. The thesis depends on the PYLARIFY commercial pipeline (US PSMA-PET share defense + Medicare reimbursement + clinical-utility + revenue growth) plus the radioligand-therapy + DEFINITY + TechneLite pipeline (PNT2002 Phase 3 readout and launch + DEFINITY cash generation + pipeline development + bolt-on radiopharma M&A) plus the diagnose+treat flywheel plus deleveraging plus Paul Blanchfield's continued execution of the radiopharma growth playbook.